Beta Bionics (BBNX) Stock Overview
A commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BBNX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Beta Bionics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.12 |
| 52 Week High | US$32.71 |
| 52 Week Low | US$8.89 |
| Beta | 0 |
| 1 Month Change | -20.00% |
| 3 Month Change | -46.19% |
| 1 Year Change | -35.79% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -40.25% |
Recent News & Updates
Beta Bionics, Inc.'s (NASDAQ:BBNX) Popularity With Investors Under Threat As Stock Sinks 58%
Feb 06
Pharmacy-Driven Diabetes Technology Adoption Will Support A Stronger Long-Term Outlook
Catalysts About Beta Bionics Beta Bionics develops automated insulin delivery systems aimed at simplifying diabetes management for people using insulin pumps. What are the underlying business or industry changes driving this perspective?We're Hopeful That Beta Bionics (NASDAQ:BBNX) Will Use Its Cash Wisely
Jan 10Beta Bionics: It Has Been An Interesting Year
Dec 09Recent updates
Beta Bionics, Inc.'s (NASDAQ:BBNX) Popularity With Investors Under Threat As Stock Sinks 58%
Feb 06Pharmacy-Driven Diabetes Technology Adoption Will Support A Stronger Long-Term Outlook
Catalysts About Beta Bionics Beta Bionics develops automated insulin delivery systems aimed at simplifying diabetes management for people using insulin pumps. What are the underlying business or industry changes driving this perspective?We're Hopeful That Beta Bionics (NASDAQ:BBNX) Will Use Its Cash Wisely
Jan 10Beta Bionics: It Has Been An Interesting Year
Dec 09Beta Bionics, Inc. (NASDAQ:BBNX) Looks Just Right With A 35% Price Jump
Oct 30Companies Like Beta Bionics (NASDAQ:BBNX) Are In A Position To Invest In Growth
Sep 22Beta Bionics: Slowing Down Or Being Conservative?
Apr 24Beta Bionics: A Sugar Rush For This IPO
Feb 02Shareholder Returns
| BBNX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.2% | 0.6% | 1.4% |
| 1Y | -35.8% | -9.5% | 13.2% |
Return vs Industry: BBNX underperformed the US Medical Equipment industry which returned -10.3% over the past year.
Return vs Market: BBNX underperformed the US Market which returned 14% over the past year.
Price Volatility
| BBNX volatility | |
|---|---|
| BBNX Average Weekly Movement | 13.9% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BBNX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BBNX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 407 | Sean Saint | www.betabionics.com |
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.
Beta Bionics, Inc. Fundamentals Summary
| BBNX fundamental statistics | |
|---|---|
| Market cap | US$650.68m |
| Earnings (TTM) | -US$77.84m |
| Revenue (TTM) | US$88.57m |
Is BBNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBNX income statement (TTM) | |
|---|---|
| Revenue | US$88.57m |
| Cost of Revenue | US$40.29m |
| Gross Profit | US$48.28m |
| Other Expenses | US$126.12m |
| Earnings | -US$77.84m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 17, 2026
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 54.51% |
| Net Profit Margin | -87.89% |
| Debt/Equity Ratio | 0% |
How did BBNX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/11 06:47 |
| End of Day Share Price | 2026/02/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beta Bionics, Inc. is covered by 16 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |